Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of titrated tolvaptan in adults with autosomal dominant polycystic kidney disease
2014-001516-19Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Long-term safety of tolvaptan. Started Sep 2014; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2014-001516-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001516-19.